NEWRegulation
Purdue Pharma (PDP) Receives $5.5 Billion Sentence for Opioid Misconduct
Published on 4/29/2026

AI Summary
Purdue Pharma has been sentenced to $5.5 billion in fines and penalties following its guilty plea in 2020 for fraudulently marketing OxyContin. This resolution allows the company to file for bankruptcy and allocate funds to a $7.4 billion settlement for victims of the opioid crisis. U.S. District Judge Madeline Cox Arleo noted that accountability has been limited since the Department of Justice did not charge individual executives, leaving most of the fines unpaid as Purdue directs assets toward repaying creditors. The developments are significant as they may influence future corporate accountability in similar cases.
Related News

Regulation
U.S. Sanctions Risk for Banks Involved with Chinese Teapot Refineries
Apr 29

Regulation
Southern Poverty Law Center testimony request impacts political landscape
Apr 29

Regulation
White House AI Guidance May Affect Anthropic (ANTH) Market Dynamics
Apr 29

Regulation
Midland States Bancorp (MOSB) Form 144 Filed on April 28, 2023
Apr 28